LRRFIP1 Antibody
| Code | Size | Price |
|---|
| PSI-6219-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-6219-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
LRRFIP1 Antibody: GCF2, TRIP, FLAP1, GCF-2, FLAP-1, HUFI-1, FLIIAP1, GCF2, Leucine-rich repeat flightless-interacting protein 1, GC-binding factor 2, LRR FLII-interacting protein 1
Application Note:
LRRFIP1 antibody can be used for detection of LRRFIP1 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
LRRFIP1 Antibody: LRRFIP1, also known as GC-binding factor 2 (GCF2), is a 738 amino acid transcriptional repressor that mainly plays a cytoskeletal role. It is primarily localized in the cytoplasm and preferentially binds to GC-rich dsDNA, but will also bind directly to dsRNA as well. The RNA binding domain encompasses a lysine-rich motif. LRRFIP1 interacts with the mammalian Flightless I (Fli-I) and is a key component in the cytoskeletal regulation of platelet function. LRRFIP1 and the related protein LRRFIP2 may modulate canonical WNT signaling and mediate the IRF3-induced production of type I interferon via a beta-catenin-dependent pathway.
Background References:
- Rikiyama T, Curtis J, Oikawa M, et al. GCF2: expression and molecular analysis of repression. Biochim. Biophys. Acta 2003; 1629:15-25.
- Suriano AR, Sanford AN, Kim N, et al. GCF2/LRRFIP1 represses tumor necrosis factor α expression. Mol. Cell. Biol. 2005; 25:9073-81.
- Wilson SA, Brown EC, Kingsman AJ, et al. TRIP: a novel double-stranded RNA binding protein which interacts with the leucine-rich repeat of Flightless I. Nucleic Acids Res. 1998; 26:3460-7.
- Goodall AH, Burns P, Salles I, et al. Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. Blood 2010; 116:4646-56.
Buffer:
LRRFIP1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
LRRFIP1 antibody was raised against a 19 amino acid synthetic peptide near the carboxy terminus of human LRRFIP1.
The immunogen is located within the last 50 amino acids of LRRFIP1.
The immunogen is located within the last 50 amino acids of LRRFIP1.
NCBI Gene ID #:
9208
NCBI Official Name:
leucine rich repeat (in FLII) interacting protein 1
NCBI Official Symbol:
LRRFIP1
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_001131024
Protein GI Number:
212276096
Purification:
LRRFIP1 Antibody is affinity chromatography purified via peptide column.
Research Area:
Signal Transduction
SPECIFICITY:
LRRFIP1 antibody is predicted to not cross-react with other LRRFIP family members. Three isoforms of LRRFIP1 are known to exist; this antibody will only recognize the two longer isoforms.
Swissprot #:
Q32MZ4
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | LRRFIP1 Peptide | PSI-6219P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|